Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: Interaction with hepatitis B virus X protein

Carcinogenesis

Volumn 31, Issue 8, 2010, Pages 1475-1482

  Gouas, Doriane A ^a   Shi, Hong ^a   Hautefeuille, Agnès H ^a   Ortiz Cuaran, Sandra L ^a   Legros, Pénélope C ^a   Szymanska, Katarzyna J ^a   Galy, Olivier ^a,b   Egevad, Lars A ^a,d   Abedi Ardekani, Behnoush ^a,c   Wiman, Klas G ^d   Hantz, Olivier ^b   de Fromentel, Claude Caron ^b,e   Chemin, Isabelle A ^b   Hainaut, Pierre L ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITÉ LYON 1   (France)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B; ARGININE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HEPATITIS B VIRUS X PROTEIN; PROTEIN P53; SERINE;

ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CODON; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; GENE; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MUTANT; PRIORITY JOURNAL; RISK FACTOR; RNA INTERFERENCE; TP53 GENE; TRANSACTIVATION;

EID: 77955388300     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq118     Document Type: Article

References (37)

1. Parkin,D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. 1 and hepatitis B virus in hepatocarcinogenesis. Liver Int., 23, 405-409.
3. Bressac,B. et al. (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 350, 429-431.
4. Hsu,I.C. et al. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
5. Shen,H.M. et al. (1996) Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res., 366, 23-44.
6. Besaratinia,A. et al. (2009) In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology, 137, 1127-1137.
7. Aguilar,F. et al. (1993) Aflatoxin B1 induces the transversion of G-> Tin codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl Acad. Sci. USA, 90, 8586-8590.
8. Denissenko,M.F. et al. (1998) The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene, 17, 3007-3014.
9. Puisieux,A. et al. (1991) Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res., 51, 6185-6189.
10. Brosh,R. et al. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer, 9, 701-713.
11. Oren,M. et al. (2010) Mutant p53 Gain-of-Function in Cancer. Cold Spring Harb. Perspect. Biol., 2, a001107.
12. Bergamaschi,D. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402.
13. Gaiddon,C. et al. (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol., 21, 1874-1887.
14. Marin,M.C. et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet., 25, 47-54.
15. Strano,S. et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem., 277, 18817-18826.
16. Crook,T. et al. (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79, 817-827.
17. Dearth,L.R. et al. (2007) Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis, 28, 289-298.
18. Forrester,K. et al. (1995) Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10, 2103-2111.
19. Bullock,A.N. et al. (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene, 19, 1245-1256.
20. Ponchel,F. et al. (1994) Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res., 54, 2064-2068.
21. Ghebranious,N. et al. (1998) The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology, 27, 967-973.
22. Wang,X.W. et al. (1994) Hepatitis B virus X protein inhibits p53 sequencespecific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA, 91, 2230-2234.
23. Jiang,W. et al. (2010) Cooperation of tumor-derived HBx mutants and p53249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int. J. Cancer. doi:10.1002/ijc.25118.
24. Oefinger,P.E. et al. (1981) Induction of hepatitis B surface antigen in human hepatoma-derived cell lines. J. Gen. Virol., 53, 105-113.
25. Bontron,S. et al. (2002) Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2. J. Biol. Chem., 277, 38847-38854.
26. Cougot,D. et al. (2007) The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J. Biol. Chem., 282, 4277-4287.
27. Verhaegh,G.W. et al. (1997) Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. Mol. Cell. Biol., 17, 5699-5706.
28. Szymañska,K. et al. (2004) Ser-249 TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int. J. Cancer, 110, 374-379.
29. Szymañska,K. et al. (2009) TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol. Biomarkers Prev., 18, 1638-1643.
30. Hollstein,M.C. et al. (1993) p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer, 53, 51-55.
31. Ang,H.C. et al. (2006) Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J. Biol. Chem., 281, 21934-21941.
32. Diao,J. et al. (2001) X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev., 12, 189-205.
33. Takada,S. et al. (1997) Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene, 15, 1895-1901.
34. Elmore,L.W. et al. (1997) Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl Acad. Sci. USA, 94, 14707-14712.
35. Ma,N.F. et al. (2008) COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin. Cancer Res., 14, 5061-5068.
36. Friedler,A. et al. (2004) Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". J. Mol. Biol., 336, 187-196.
37. Kato,S. et al. (2003) Understanding the function-structure and functionmutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA, 100, 8424-8429.